MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of common stock,...
$98,514K
Maturities of investments
$74,000K
Net cash provided by
financing activities
$94,335K
Net cash provided by
(used in) investing...
$11,394K
Canceled cashflow
$4,179K
Canceled cashflow
$62,606K
Net increase in
cash, cash...
$33,442K
Canceled cashflow
$72,287K
Tax payments
related to shares...
$4,179K
Accounts payable
$15,888K
Stock-based compensation
expense
$11,269K
Amortization of intangible
assets
$5,716K
Depreciation and
amortization of property and...
$2,823K
Amortization of right of use
asset
$1,876K
Trade accounts
receivable
-$690K
Unrealized foreign
exchange loss
-$434K
Loss on asset
disposals
-$28K
Purchase of investments
$55,998K
Purchase of property and
equipment
$6,608K
Net cash used in
operating activities
-$72,074K
Effect of foreign
exchange rate changes
-$213K
Canceled cashflow
$38,724K
Net sales
$71,430K
Net loss
-$79,045K
Canceled cashflow
$71,430K
Accrued expenses and
other liabilities
-$21,038K
Inventory
$4,931K
Operating lease
liabilities
-$2,027K
Prepaid expenses, other
assets and long-term...
$1,466K
Accretion of discounts and
premiums on investments
$1,120K
Deferred tax benefit
expense
-$665K
Excess and
obsolescence reserve
-$506K
Total expenses
$107,977K
Total cost of sales
$42,498K
Research and development
$57,370K
General and
administrative
$18,699K
Sales and marketing
$15,116K
Depreciation and
amortization
$8,539K
Other segment items
$8,253K
Cost of goods sold
(excluding depreciation...
$38,829K
Royalties
$2,650K
Stock-based compensation
$1,019K
Back
Back
Cash Flow
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
source: myfinsight.com